OBJECTIVE: The aim of our study was to assess the costs of SSc and to analyse cost drivers. METHODS: A cross-sectional survey of consecutive patients with SSc was performed in a rheumatology centre in Hungary. Clinical characteristics, the European Scleroderma Study Group activity index, disease severity scale (DSS), scleroderma HAQ (S-HAQ) and health care utilization were recorded. Cost calculation was performed and correlation with clinical variables was analysed. Results were compared with RA and PsA. RESULTS: Eighty patients were involved: 72 (90%) women, mean age (s.d.) 57.4 (9.6) years and disease duration of 6.2 (6.6) years and 25% of the cases had dcSSc. Mean total cost was 9619 (s.d. 6444) euros/patient/year with rate of indirect cost being 56%. Disability-related productivity loss (55.2%) and hospitalization (28.3%) were the highest among the cost items. Patients with dcSSc had significantly higher direct costs (P = 0.005) compared with the lcSSc subset. Disease activity showed significant correlation with total costs, DSS and S-HAQ with direct costs. SSc-related costs were higher than in matched RA and PsA cases. CONCLUSIONS: The cost-of-illness of SSc is high with a dominance of productivity loss related costs. Moreover, the disease activity is an important cost driver.
OBJECTIVE: The aim of our study was to assess the costs of SSc and to analyse cost drivers. METHODS: A cross-sectional survey of consecutive patients with SSc was performed in a rheumatology centre in Hungary. Clinical characteristics, the European Scleroderma Study Group activity index, disease severity scale (DSS), sclerodermaHAQ (S-HAQ) and health care utilization were recorded. Cost calculation was performed and correlation with clinical variables was analysed. Results were compared with RA and PsA. RESULTS: Eighty patients were involved: 72 (90%) women, mean age (s.d.) 57.4 (9.6) years and disease duration of 6.2 (6.6) years and 25% of the cases had dcSSc. Mean total cost was 9619 (s.d. 6444) euros/patient/year with rate of indirect cost being 56%. Disability-related productivity loss (55.2%) and hospitalization (28.3%) were the highest among the cost items. Patients with dcSSc had significantly higher direct costs (P = 0.005) compared with the lcSSc subset. Disease activity showed significant correlation with total costs, DSS and S-HAQ with direct costs. SSc-related costs were higher than in matched RA and PsA cases. CONCLUSIONS: The cost-of-illness of SSc is high with a dominance of productivity loss related costs. Moreover, the disease activity is an important cost driver.
Authors: K Érsek; T Kovács; A Wimo; K Kárpati; V Brodszky; M Péntek; L Jönsson; A Gustavsson; D McDaid; P A Kenigsberg; H Valtonen; L Gulácsi Journal: J Nutr Health Aging Date: 2010-10 Impact factor: 4.075
Authors: Manjit K Singh; Philip J Clements; Daniel E Furst; Paul Maranian; Dinesh Khanna Journal: Arthritis Care Res (Hoboken) Date: 2012-02 Impact factor: 4.794
Authors: Fanni Rencz; László Gulácsi; Michael Drummond; Dominik Golicki; Valentina Prevolnik Rupel; Judit Simon; Elly A Stolk; Valentin Brodszky; Petra Baji; Jakub Závada; Guenka Petrova; Alexandru Rotar; Márta Péntek Journal: Qual Life Res Date: 2016-07-29 Impact factor: 4.147